Suppr超能文献

给予内源性大麻素可预防与膀胱炎症相关的牵涉性痛觉过敏。

Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.

作者信息

Farquhar-Smith W P, Rice A S

机构信息

Department of Anaesthetics, Imperial College School of Medicine, London, United Kingdom.

出版信息

Anesthesiology. 2001 Mar;94(3):507-13; discussion 6A. doi: 10.1097/00000542-200103000-00023.

Abstract

BACKGROUND

Referred hyperalgesia to a somatopically appropriate superficial site is a cardinal symptom of visceral inflammatory pain and has been demonstrated after turpentine-induced urinary bladder inflammation in the rat. The authors examined the effect of the endocannabinoids anandamide and palmitoylethanolamide on the referred hyperalgesia associated with this model.

METHODS

After measurement of baseline limb withdrawal latencies to a noxious heat stimulus, the bladders of 50 female Wistar rats were inflamed by intravesical administration of 0.5 ml 50% turpentine. Ten or 25 mg/kg of anandamide or palmitoylethanolamide or vehicle were administered immediately before introduction of turpentine. Antagonists to both the cannabinoid CB1 and CB2 receptors were coadministered with the higher dose of endocannabinoids. Latencies were recorded 2, 4, 6, 8, and 24 h after removal of turpentine. The difference between forelimb and hind limb withdrawal latencies was plotted against time, and areas under these curves were compared.

RESULTS

Inflammation of the urinary bladder was associated with a relative thermal hyperalgesia referred to the hind limb. Anandamide and palmitoylethanolamide attenuated this referred hyperalgesia at doses of 10 and 25 mg/kg. The CB1 receptor antagonist SR141716A reduced the antihyperalgesic effect of anandamide, but the CB2 antagonist SR144528 did not. Coadministration of SR141716A with palmitoylethanolamide did not affect the antihyperalgesic effect but was reduced by SR144528.

CONCLUSIONS

Anandamide (via CB1 receptors) and palmitoylethanolamide (putatively via CB2 receptors) attenuated a referred hyperalgesia in a dose-dependent fashion. CB1 and CB2 receptors are strategically situated to influence the nerve growth factor-driven referred hyperalgesia associated with inflammation of the urinary bladder. These data implicate cannabinoids as a novel treatment for vesical pain.

摘要

背景

牵涉痛至躯体感觉对应区的浅表部位是内脏炎性疼痛的主要症状,在大鼠松节油诱导的膀胱炎症后已得到证实。作者研究了内源性大麻素花生四烯乙醇胺和棕榈酰乙醇胺对该模型相关牵涉痛觉过敏的影响。

方法

在测量对有害热刺激的基线肢体退缩潜伏期后,通过膀胱内注射0.5 ml 50%松节油使50只雌性Wistar大鼠的膀胱发炎。在引入松节油之前立即给予10或25 mg/kg的花生四烯乙醇胺或棕榈酰乙醇胺或赋形剂。将大麻素CB1和CB2受体的拮抗剂与较高剂量的内源性大麻素共同给药。在去除松节油后2、4、6、8和24小时记录潜伏期。将前肢和后肢退缩潜伏期的差异与时间作图,并比较这些曲线下的面积。

结果

膀胱炎症与后肢的相对热痛觉过敏相关。花生四烯乙醇胺和棕榈酰乙醇胺在10和25 mg/kg剂量下减轻了这种牵涉痛觉过敏。CB1受体拮抗剂SR141716A降低了花生四烯乙醇胺的抗痛觉过敏作用,但CB2拮抗剂SR144528没有。SR141716A与棕榈酰乙醇胺共同给药不影响抗痛觉过敏作用,但被SR144528降低。

结论

花生四烯乙醇胺(通过CB1受体)和棕榈酰乙醇胺(可能通过CB2受体)以剂量依赖性方式减轻牵涉痛觉过敏。CB1和CB2受体处于战略位置,可影响与膀胱炎症相关的神经生长因子驱动的牵涉痛觉过敏。这些数据表明大麻素是膀胱疼痛的一种新的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验